Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
19.6M
-
Number of holders
-
8
-
Total 13F shares, excl. options
-
396K
-
Shares change
-
+339K
-
Total reported value, excl. options
-
$714K
-
Value change
-
+$552K
-
Number of buys
-
5
-
Number of sells
-
-3
-
Price
-
$1.80
Significant Holders of Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) as of Q2 2023
11 filings reported holding ENSC - Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share as of Q2 2023.
Ensysce Biosciences, Inc. - Common Stock, par value $0.0001 per share (ENSC) has 8 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 396K shares
of 19.6M outstanding shares and own 2.02% of the company stock.
Largest 10 shareholders include SABBY MANAGEMENT, LLC (322K shares), Anson Funds Management LP (36.3K shares), GSA CAPITAL PARTNERS LLP (17.5K shares), VANGUARD GROUP INC (15.4K shares), Tower Research Capital LLC (TRC) (3.9K shares), BlackRock Inc. (975 shares), WOLVERINE ASSET MANAGEMENT LLC (12 shares), WELLS FARGO & COMPANY/MN (10 shares), Virtu Financial LLC (0 shares), and Powell Investment Advisors, LLC (0 shares).
This table shows the top 8 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.